2014

1. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA-ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; [Epub ahead of print].

2. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U. Comparison of PET imaging with a 68Ga-labelled PSMA-ligand and 18F-choline based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nuc Med Mol Imaging 2014;41(1):11-20. doi: 10.1007/s00259-013-2525-5.

3. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014;41(5):887-897.

4. Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, Gnirs R, Roethke MC, Schlemmer HP, Haberkorn U. Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol 2014; pii: nou131. [Epub ahead of print].

5. Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blöcker IM, Bahtz R, Komorowski L, Stöcker W, Kastrup A, Kuthe M, Meinck HM. Progressive encephalomyelitis with rigidity and myoclonus: A new variant with DPPX antibodies. Neurology 2014; 82(17):1521-8. doi: 10.1212/WNL.0000000000000372.

6. Cheng C, Alt V, Pan L, Thormann U, Schnettler R, Strauss LG, Schumacher M, Gelinsky M, Dimitrakopoulou-Strauss A. Preliminary evaluation of different biomaterials for defect healing in an experimental osteoporotic rat model with dynamic PET-CT (dPET-CT) using F-18-Sodium Fluoride (NaF). Injury 2014;45(3):501-5. doi: 10.1016/j.injury.2013.11.023.

7. Cheng C, Alt V, Pan L, Thormann U, Schnettler R, Strauss LG, Heinemann S, Schumacher M, Gelinsky M, Nies B, Dimitrakopoulou-Strauss A. Application of F-18-Sodium Fluoride (NaF) Dynamic PET-CT (dPET-CT) for Defect Healing: A Comparison of Biomaterials in an Experimental Osteoporotic Rat Model. Med Sci Monit 2014;20:1942-1949.

8. Dimitrakopoulou-Strauss A, Frenkel A, Epelbaum R. Reply: Comment on: "Tumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic 18F-FDG PET/CT". J Nucl Med 2014 Feb;55(2):351-2. doi: 10.2967/jnumed.113.132845. 

9. Dimitrakopoulou-Strauss A. PET-CT in der nuklearmedizinischen Diagnostik des multiplen Myeloms. Radiologe 2014;54:564-571.

10. Doberstein K, Harter PN, Haberkorn U, Bretz NP, Arnold B, Carretero R, Moldenhauer G, Mittelbronn M, Altevogt P. Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT. Int J Cancer 2014; doi:10.1002/ijc. 29222. [Epub ahead of print].

11. Eder M, Schaefer M, Bauder-Wuest U, Haberkorn U, Eisenhut M, Kopka K. Preclinical Evaluation of a Bispecif|c Low-Molecular Heterodimer Targeting Both PSMA and GRPR for Improved PET Imaging and Therapy of Prostate Cancer. Prostate 2014;74(6):659-668.

12. Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (Basel) 2014; 7(7):779-796.

13. Flechsig P, Kratochwil C, Schwartz LH, Rath D, Moltz J, Antoch G, Heussel C-P, Rieser M, Warth A, Zabeck H, Kauczor H-U, Haberkorn U, Giesel FL. Quantitative Volumetric CT-Histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer. J Nucl Med 2014; 55(4):559-564.

14. Haberkorn U, Mier W, Dimitrakopoulou-Strauss A, Eder M, Kopka K, Altmann A. Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. Clin Transl Imaging 2014;2:33-41.

15. Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, Gladkich J, Nwaeburu CC, Mattern J, Mollenhauer M, Rückert F, Zach S, Haberkorn U, Gross W, Schönsiegel F, Bazhin AV, Herr, I. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget 2014;5(13):5177-89.

16. Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U, Giesel FL. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Mol Imaging Biol 2014; [Epub ahead of print].

17. Kratochwil C, Mavriopoulou E, Rath D, Afshar-Oromieh A, Apostolopoulos D, Haufe S, Mier W, Haberkorn U, Giesel FL. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy. Q J Nucl Med Mol Imaging 2014; [Epub ahead of print].

18. Kratochwil C, Giesel FL. [Radionuclide therapy of endocrine-related cancer.] Radiologe 2014;54(10):1007-1015.

19. Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, Haberkorn U, Giesel FL. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol 2014;16(3):434-40. doi: 10.1093/neuonc/not199.

20. Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014;41(11):2106-19. 

21. Kristen AV, Scherer K, Buss S, Aus dem Siepen F, Haufe S, Bauer R, Hinderhofer K, Giannitsis E, Hardt S, Haberkorn U, Katus HA, Steen H. Noninvasive Risk Stratification of Patients With Transthyretin Amyloidosis. JACC Cardiovasc Imaging 2014;7(5):502-10.

22. Lehmann LH, Rostosky JS, Buss SJ, Kreusser MM, Krebs J, Mier W, Enseleit F, Spiger K, Hardt SE, Wieland T, Haass M, Lüscher TF, Schneider MD, Parlato R, Gröne HJ, Haberkorn U, Yanagisawa M, Katus HA, Backs J. Essential role of sympathetic endothelin A receptorsfor adverse cardiac remodeling. Proc Natl Acad Sci U S A 2014;111(37):13499- 504. doi: 10.1073/pnas.1409026111.

23. Mickan A, Sarko D, Haberkorn U, Mier W. Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics. Curr Pharm Biotechnol 2014;15(3): 200-9.

24. Mier W, Babich J, Haberkorn U. Is nano too big? Eur J Nucl Med Mol Imaging 2014;41:4-6.

25. Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, Friebe M, Eisenhut M, Enk A, Haberkorn U. Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide 131I-BA52. J Nucl Med 2014;55:9-14. doi: 10.2967/jnumed.112.112789.

26.  Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. Cyclosporin A inhibits Hepatitis B and Hepatitis D Virus entry by Cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014;60(4):723-731.

27. Ronellenfitsch U, Wängler B, Niedermoser S, Dimitrakopoulou-Strauss A, Hohenberger P.Bedeutung der PET für die Chirurgie des gastrointestinalen Stromatumors. Chirurg 2014; 85:493-499.

28. Sachpekidis C, Goldschmidt H, Hose D, Pan L, Cheng C, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A. PET/CT studies of multiple myeloma using 18F-FDG and 18F-NaF: comparison of distribution patterns and tracers' pharmacokinetics. Eur J Nucl Med Mol Imaging 2014;41(7):1343-53. doi: 10.1007/s00259-014-2721-y.

29. Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging 2014; [Epub ahead of print].

30. Sugiura G, Kühn H, Sauter M, Haberkorn U, Mier W. Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs. Molecules 2014;19:2135-2165. doi:10.3390/molecules 19022135.

31. Talanow R, Giesel F. Honoring our helpers. J Radiol Case Rep 1;8(1):49-52.

32. Thomann S, Longerich T, Bazhin AV, Mier W, Schemmer P, Ryschich E. Selective targeting of liver cancer with the endothelial marker CD146. Oncotarget 2014;5(18):8614-24.

33. Uhl P, Fricker G, Haberkorn U, Mier W. Current Status in the Therapy of Liver Diseases. Int J Mol Sci 2014;15(5):7500-12. doi: 10.3390/ijms15057500.

34. Uhl P, Fricker G, Haberkorn U, Mier W. Radionuclides in drug development. Drug Discov Today 2014; pii: S1359-6446(14)00396-1. doi: 10.1016/j.drudis.2014.09.027. [Epub ahead of print] Review.

35. Winter MC, Haberkorn U, Kratochwil C. [Importance of nuclear medicine diagnostics in CUP syndrome.] Radiologe 2014;54(2):134-9. doi: 10.1007/s00117-013-2548-8.

36. Wulfert S, Kratochwil C, Choyke PL, Afshar-Oromieh A, Mier W, Kauczor HU, Schenk JP, Haberkorn U, Giesel FL. Multimodal Imaging for Early Functional Response Assessment of 90Y-/ 177Lu-DOTATOC Peptide Receptor Targeted Radiotherapy with DW-MRI and 68Ga-DOTATOC-PET/CT. Mol Imaging Biol 2014;16(4):586-94. doi: 10.1007/s11307-014-0722-7.

37. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first therapy results with a 124I/ 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014;41(7):1280-92. doi: 10.1007/s00259-014-2713-y.

1. Mehndiratta A, Tee YK, Payne SJ, Chappell MA, Giesel FL. An Introduction to Brain Tumor Imaging. In: Hayat MH. (ed), Tumors of the Central Nervous System. Springer-Verlag 2014, Volume 1, pp 3-20. ISBN 978-94-007-7036-2.

2. Mehndiratta A, Anandaraj P, Zechmann C, Giesel FL. Nuclear Medicine. An overview of Imaging Techniques, Clinical Applications and Trials. In: Miller CG, Krasnow J, Schwartz LH. (eds), Medical Imaging in Clinical Trials. Springer Verlag 2014, pp 293-325. ISBN 978-1-84882-709-7.

3. von Tengg-Kobligk H, Mehndiratta A, Giesel FL. Contrast Agents in Radiology. In: Miller CG, Krasnow J, Schwartz LH. (eds.), Medical Imaging in Clinical Trials. Springer Verlag 2014, pp 327-357. ISBN 978-1-84882-709-7.